MURFREESBORO, TN / ACCESSWIRE / July 9, 2021 / National Health Investors, Inc. (NYSE:NHI) announced details for the release of its results for the second quarter ended June 30, 2021. NHI plans to issue its earnings release after the market closes on Monday, August 9, 2021, and will host a conference call on the following day, Tuesday, August 10, 2021, at 12 p.m. Eastern Time to discuss the results. The number to call for this interactive teleconference is (800) 952-1438, with the confirmation number 21995595.
The live broadcast of the conference call will be available online at www.nhireit.com and at https://www.webcaster4.com/Webcast/Page/633/41897 on Tuesday, August 10, 2021, at 12 p.m. Eastern Time. The online replay will be available shortly after the call and remain available for one year.
About NHI
Incorporated in 1991, National Health Investors, Inc. (NYSE: NHI) is a real estate investment trust specializing in sale-leaseback, joint-venture, mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments. NHI’s portfolio consists of independent, assisted and memory care communities, entrance-fee retirement communities, skilled nursing facilities, medical office buildings and specialty hospitals. For more information, visit www.nhireit.com.
Contact:
Dana Hambly
Vice President, Investor Relations
Phone: (615) 890-9100
SOURCE: National Health Investors
View source version on accesswire.com:
https://www.accesswire.com/654954/NHI-Announces-Second-Quarter-2021-Earnings-Release-and-Conference-Call-Dates
– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI)…
D-bal-max D-Bal MAX Glasgow, June 15, 2025 (GLOBE NEWSWIRE) -- In the quest for enhanced…
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment…
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response…
After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients…
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="400px" width="600px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
